Answers are grounded in this paper and cite their sources.
Cirrhosis of the liver, known since antiquity, has been recognized as a clinical and pathologic entity for more than 450 years. It has been described, in various aspects, by some of the greatest names in medical history, including Vesalius, Harvey, Morgagni, Laennec, Rokitansky, and Frerichs. In our time, one of the principal founders of the fields of hepatology and hepatopathology, Hans Popper, wrote more than 50 of his more than 800 published papers about hepatic cirrhosis and fibrosis, including one of the first studies of reversibility of fibrosis of the liver.5Were cirrhosis a strictly morphologic condition with uniform histopathology, the thoughtful and provocative hypothesis offered by Wanless and coworkers6 would merit publication without comment. However, cirrhosis is decidedly not a strictly morphologic condition. It is, instead, a clinicopathologic disorder demonstrating considerable variation in any given histologic section. For this, and other reasons, the conclusions reached by Wanless and his colleagues must await further confirmation before they can be embraced.Two conclusions can be reached from the morphologic features that are characteristic of cirrhosis, features that have been intensely studied by many generations of pathologists. In the traditional view, cirrhosis is a dynamic and progressive disorder, modified both by its stage of development and by variation caused by the progressive and irregular growth of regenerative nodules that can mold the developing and developed septa, as well as by many other factors, including ongoing effects reflecting the etiopathogenesis of the cirrhosis as well as the direct and indirect host responses. See also pp 1585, 1589, 1591, 1592, and 1599.In the concept developed by Wanless, cirrhosis is a waxing and waning morphologic condition. Experimental and clinical studies contain reasonable evidence indicating that the fibrosis component of developing cirrhosis can diminish, at least to some degree. There is, however, still considerable doubt that advanced cirrhosis, with its associated secondary manifestations reflecting both portal hypertension and disordered hepatocyte function, can regress.It might be suggested that clinical evidence for the regression of cirrhosis will come as more and more patients are treated with medications potentially effective in modifying the etiology or host responses that contribute to the development of cirrhosis. The patient described by Wanless et al underwent a series of liver biopsies after treatment with lamivudine, an antiviral agent able to inhibit viral replication. As the authors indicate, “documentation of regression requires an ample biopsy followed by examination of the entire liver.” The definitive proof of regression in the patient cited must await either hepatic resection or autopsy. Many more patients would have to be studied over a period of years, with both serial biopsies and whole liver examination, before validating the conclusions based on the experience of this single patient.There is, thus far, no accumulated clinical evidence to support the view that cirrhosis regresses. Indeed, the introduction to the article by Wanless and colleagues indicates that “Complete regression of cirrhosis has not been clearly documented.” The prototype patient in this article is not completely described, and many questions could still be asked. Is there evidence, other than the 3 biopsy samples, that this patient did have diffuse architectural change and that it regressed? Did the patient have signs or symptoms of cirrhosis? Were there imaging studies showing cirrhosis? What happened to the liver size? Was splenomegaly confirmed and did it regress? Did ascites disappear?Ian Wanless, MD, is one of the most creative and insightful students of hepatopathology currently active. His many studies of hepatic vasculature and the ramifications of morphologic and functional vascular changes have altered our understanding of many liver diseases, including cirrhosis.7–11 The features described in the current study as “regression parameters” are regularly seen in cirrhotic livers when there has not been a therapeutic basis for regression and may well reflect atrophy and replacement of the vascular septa by expanding regenerative nodules. If one accepts the concept that cirrhosis is indeed a pathophysiologic disorder whose hallmarks are both vascular septa (not simple fibrosis) and regenerative, potentially autonomous nodules, definitive proof of regression of cirrhosis has not yet been established.Is “incomplete septal cirrhosis” the characteristic morphology of regressing cirrhosis? Is it a stage of developing cirrhosis? Or, is it a morphologic pattern seen in biopsies of macronodular cirrhosis? Ample clinical and pathologic experience supports the latter 2 concepts. The histologic picture of incomplete septal cirrhosis could also, in some cases, be a reflection of regression of fibrosis, but does not necessarily mean regression of cirrhosis.Wanless' previous contributions demand careful attention to any concept he proposes and will appropriately influence readers. It is for this reason, perhaps, that the editors have elected to solicit comments from a number of experienced hepatopathologists who have not fully endorsed the conclusions reached to be published concomitantly with this challenging study. Both the morphologic observations and the theoretical concepts of the article by Wanless et al merit consideration and, particularly, further study, but at this stage cannot be completely accepted.
No takes yet. Share an insight, caveat, or question.
Stephen A. Geller (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: